Benefits of neoadjuvant chemotherapy in NSCLC

Chest

Volumn 109, Issue 5 SUPPL., 1996, Pages 96S-101S

  Pastorino, Ugo ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0029991284     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.5_Supplement.96S     Document Type: Article

References (32)

1. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(suppl):225-33
2. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96:440-47
3. Van Raemdonck DE, Schneider A, Ginsberg RJ. Surgical treatment for higher-stage non-small cell lung cancer. Ann Thorac Surg 1992; 51:999-1013
4. Decker DA, Dines DE, Payne WS, et al. The significance of cytologically negative pleural effusion in bronchogenic carcinoma. Chest 1978; 74:640-42
5. Brunner KW, Marthaler T, Muller W. Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-2627.2) for radically resected bronchogenic carcinoma. Cancer Chemother Rep 1973; 4:125-32
6. Shields TW, Higgins GA Jr, Humphrey EW, et al. Prolonged intermittent adjuvant chemotherapy with CCNU and hydraxyurea after resection of carcinoma of the lung. Cancer 1982; 50: 1713-21
7. Lad T, Rubinstein L, Sadeghi A, et al. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. J Clin Oncol 1988; 6:9-17
8. Holmes EC, Gail M, Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferenriated carconoma. J Clin Oncol 1986; 4:710-15
9. Ayoub J, Vigneault E, Hanley J, et al. The Montreal multicenter trial in operable non-small cell lung cancer (NSCLC): a multivariate analysis of the predictors of relapse [abstract]. Proc Am Soc Clin Oncol 1991; 10:247
10. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer: the Lung Cancer Study Group. J Natl Cancer Inst 1993; 85:299-306
11. Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J Clin Oncol 1992; 10:1927-32
12. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365-73
13. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with MVP (mitomycin-c+vindesine+cisplatin) for stage III (T1-3, N2, M0) unresectable non-small cell lung cancer: the Toronto experience. Lung Cancer 1993; 9:377-82
14. Rosell R, Codina JG, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330:23-32
15. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage III non-small cell lung cancer. J Natl Cancer Inst 1994; 86:673-80
16. Minna JD, Battey JF, Brooks BJ, et al. Molecular genetic analysis reveals chromosomal alterations, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harbor Symp Quant Biol 1986; 51:843-53
17. Birrer MJ, Brown PH. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 1992; 52:2658s-64s
18. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A - a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 1991; 324:1084-90
19. Miyake M, Taki T, Hitomi S, et al. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327:14-8
20. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52:4828-31
21. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long-term survival. Br J Cancer 1993; 68:162-65
22. Tateishi M, Ishida T, Mitsudomi T, et al. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27:1372-75
23. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993; 329:690-94
24. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323:561-65
25. Bunn PA Jr, Van Zandwijk N, Pastorino U, et al. European School of Oncology: First Euro-American Forum on Lung Cancer Treatment. Eur J Cancer 1994; 30:710-13
26. Hong WK, Lippman JM, Itri L, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801
27. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 7:1216-22
28. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 1992; 7:1989-97
29. Sozzi G, Miozzo M, Tagliabue E, et al. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 1991; 51:400-04
30. Pastorino U, Sozzi G, Miozzo M, et al. Genetic changes in lung cancer. J Cell Biochem 1993; 17F:237-48
31. Gebert J, Moghab N, Frangioni JV, et al. High frequency of retinoic acid receptor b abnormalities in human lung cancer. Oncogene 1991; 6:1859-68
32. Xu XC, Sozzi G, Ro J, et al. Detection by in situ hybridization of a low expression of nuclear retinoic acid receptors beta (RAR-b) but not of RAR-a or RAR-g in human lung cancer specimens [Seventh IASLC Conference abstract 093]. Lung Cancer 1994; 11(suppl 1):25